Our Leadership Team

Our leaders are passionate, empowered and committed to our mission to make a difference in the lives of patients.

Leadership Team

A real Jeff of all trades, you'll find this adventurous CEO catching waves on his 9-foot Mega Magic longboard...that is, when he's not busy roasting his own coffee beans.

Jeff Jonas, M.D.

Chief Executive Officer
Member of Board of Directors

Jeff joined SAGE as CEO in 2013 and has more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the CNS field. Before joining the SAGE team, Jeff served as President of the Regenerative Medicine Division of Shire plc and previously as Senior Vice President of Research and Development, Pharmaceuticals at Shire. Prior to Shire, he served as the Executive Vice President of ISIS Pharmaceuticals, as the Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and in senior-level positions at Upjohn Laboratories. Jeff founded AVAX Technologies, where he served as CEO and President, and SCEPTOR Industries, where he served as Chairman, President and Chief Technology Officer. Earlier in his career, he served as Independent Director at Cara Therapeutics, Inc. and Director of AVAX Technologies. He has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts, and has received numerous awards.

Jeff received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard and then served as Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School.

When he's not cooking meals for his family and friends, Steve enjoys serving as head coach of the all-girl robotics team, the "Radical Robots," in Swarthmore, PA.

Steve Kanes, M.D., Ph.D.

Chief Medical Officer

Steve joined SAGE as CMO in 2013. Steve is a former practicing psychiatrist and previously served as the Executive Director/Therapeutic Area Clinical Director for the inflammation, neuroscience and respiratory GMED division of AstraZeneca Pharmaceuticals. At AstraZeneca, he also served as the Chair of the Neuroscience Safety Knowledge Group. During his time at AstraZeneca, Steve served as the Medical Science Senior Director for the neuroscience established brands and emerging anesthesia group product team and in other positions of increasing responsibility in the neuroscience discovery medicine, early and late development groups. Prior to joining AstraZeneca, he was a faculty member in the psychiatry department at the University of Pennsylvania School of Medicine, where he continues to serve as an adjunct assistant professor of psychiatry. Steve has authored or co-authored more than 30 peer-reviewed publications. He serves as an ad hoc reviewer for the journals Neuropsychopharmacology, American Journal of Medical Genetics and Biological Psychiatry.

Steve received his B.A. from the University of Pennsylvania and both his Ph.D. and M.D. from State University of New York, Stony Brook. He completed his psychiatry residency at Yale-New Haven Medical Center and postdoctoral fellowship at the University of Pennsylvania.

When Al’s not discovering new medicines, he is spending his time in the water, under the water or on the water. He loves diving, white water rafting, wake boarding – anything that gets him into a body of water!

Al Robichaud, Ph.D.

Chief Scientific Officer

Al joined SAGE as CSO in 2011, with more than 20 years of drug discovery experience focused primarily in the neuroscience arena. Most recently, he was Vice President of Chemistry and Pharmacokinetic Sciences at Lundbeck USA, where he was responsible for the drug discovery, analytical, computational and pharmacokinetics departments focused on synaptic transmission and neuroinflammation. Prior to Lundbeck, Al was Senior Director and Head of the Neuroscience Discovery Chemistry Department of Wyeth Research. During his tenure there, his group successfully delivered more than 15 drug candidates into clinical development in a broad range of neuroscience indications. Al has co-authored more than 125 manuscripts and abstracts, and is a co-inventor on 50 patents and patent applications.

Al holds a B.S. in chemistry from Rensselaer Polytechnic Institute, a Ph.D. in organic chemistry from the University of California, Irvine and was an American Chemical Society postdoctoral fellow at Colorado State University.

A chemist turned CFO, Kimi feels as comfortable crunching numbers as she does creating compounds. Perhaps she's most in her element when she trades ions for irons out on the golf course, where you'll find her in her free time.

Kimi Iguchi, CPA

Chief Financial Officer

Kimi joined SAGE as CFO in 2013, bringing both financial and operating strength from her senior management experience at Millennium, Biogen and emerging life science companies. Prior to joining SAGE, Kimi served as the Chief Operating Officer, North America, for Santhera Pharmaceuticals. Prior to that, she held the role of Vice President of Finance at Cyberkinetics Neurotechnology Systems. Previously, Kimi was the Senior Director of Financial Reporting and Analysis at Millennium Pharmaceuticals and the Senior Manager of External Reporting at Biogen, Inc. She also worked as a business assurance manager at PricewaterhouseCoopers LLP and started her career in chemistry-related positions at various Boston-based companies.

Kimi holds a B.A. in chemistry from Drew University and an MBA from Northeastern University. She earned her CPA in Massachusetts.

From engineering offshore pipelines and platforms in the North Sea and Gulf of Mexico, to running his boat or grooving trails on the ski slopes, one thing is clear: Tom the builder loves to build (and a good adventure)!

Tom Anderson

Chief Commercial Strategy Officer

Tom joined SAGE in April 2014 as Chief Commercial Strategy Officer. Prior to SAGE, Tom served as Senior Vice President, Corporate Strategy and Commercial Assessment at Shire plc and served as General Manager for several of Shire’s psychiatry and neurology products. In addition, he led Shire’s specialty pharmaceutical commercial operations, business information and strategic marketing functions, and played a lead role in business development efforts. Prior to Shire and in two separate tenures, he spent 17 years in Johnson & Johnson’s pharmaceutical companies, notably Janssen and Ortho-McNeil, where he held senior-level roles in marketing, marketing research, sales and sales management, operations and engineering. In between employments at Johnson & Johnson, he was President and Chief Executive Officer of Ranir Corporation – a dental products company – where he was also a Corporate Officer and Director, and Executive Vice President and Chief Operating Officer of Lander Co., Inc., a healthcare-related consumer packaged goods company, where he was previously a Corporate Officer.

Tom holds a B.S. in civil engineering from Lehigh University and an MBA in finance from the University of Notre Dame.

Jim is an avid sports fan, and when he's not at SAGE, you'll find him playing golf, softball, Ultimate Frisbee or tennis (though lately, he admits he's more likely to be watching said sports on TV).

Jim Doherty, Ph.D.

Senior Vice President of Research

Jim joined SAGE in 2012 with more than 14 years of experience in neuroscience drug discovery and development. He most recently served as Director and Head of Neuroscience for the CNS and pain innovative medicine unit of AstraZeneca Pharmaceuticals in Sodertalje, Sweden, where he was responsible for leading preclinical research in neurology and pain control. Prior to that, he was Director and Head of the Neuroscience Department at AstraZeneca Pharmaceuticals in Wilmington, Del., where he was responsible for leading preclinical research in psychiatry and cognition. He has experience with discovery, translational science and early development in several areas of neuroscience research, including psychiatry, neurology, cognition, epilepsy and analgesia. Jim has led multiple teams to deliver candidate compounds into clinical development. He has authored more than 30 peer-reviewed research and review articles.

Jim holds a B.A. in biology from the University of Delaware and a Ph.D. in neuroscience from Georgetown University. He was a post-doctoral fellow at Emory University Medical School.

 In her free time, Anne Marie enjoys horseback riding and spending time with family.

Anne Marie Cook

Senior Vice President, General Counsel  

Anne Marie Cook joined SAGE as General Counsel in 2015. Before joining SAGE, Anne Marie served as Senior Vice President, General Counsel and Secretary at Aegerion Pharmaceuticals. Before that, she was a partner with Boston-based law firm Choate Hall & Stewart LLP (Choate), where she represented life science companies in structuring and negotiating strategic transactions such as joint ventures, collaborations, mergers and acquisitions and intellectual property. Additionally, she provided general legal support in connection with the research, development and commercialization of pharmaceutical products. Prior to joining Choate, she was Senior Vice President, Business & Corporate Development, General Counsel at ViaCell, Inc., and Chief Corporate Counsel at Biogen. 

Anne Marie holds a B.S. in biology from Tufts University and a J.D. from the University of Notre Dame Law School.

In his free time, Heinrich’s main focus is spending time with family and friends. He likes to travel and explore new activities. In order to keep up with his daughter, he started to skateboard (so far without major injuries). He also enjoys scuba-diving and sailing.

Heinrich Schlieker, Ph.D.

Senior Vice President, Technical Operations

Heinrich joined SAGE in 2015 as Senior Vice President, Technical Operations. Before joining SAGE, he served as Vice President, Process Development & Manufacturing at Cubist, Inc., where he was responsible for developing manufacturing processes for new products, all CMC related development and for overseeing external manufacturing partners for clinical stage and commercial products. Prior to his 10-year tenure at Cubist, he held various positions in process development and manufacturing support at Hoffman-La Roche in Switzerland, New Jersey and Germany.

Heinrich holds both a chemistry degree and a Ph.D. in biochemical engineering from the Braunschweig University of Technology, Germany.

Frank has played rhythm guitar in several garage bands over the last 10 years, including the newly formed “SAGE Against the Machine.”

Francesco Salituro, Ph.D.

Vice President, Chemistry

Frank joined SAGE in March 2012 as Vice President of Chemistry; he has over 28 years of drug discovery experience resulting in 12 preclinical and clinical small molecule candidates. Most recently, Frank served as Director of Medicinal Chemistry at Agios Pharmaceuticals, where he spearheaded the discovery of several drug candidates for metabolism targets, all of which are currently in human clinical trials. Prior to that, he held a leadership position at Vertex Pharmaceuticals and served as a Senior Associate Scientist at Marion Merrell Dow Pharmaceuticals. Frank has co-authored 47 scientific publications and is an inventor on 55 issued U.S. patents. He has served as Chairman of the prestigious GRC on Medicinal Chemistry in 2011, and more recently was elected to the Board of Directors for the Epilepsy Foundation New England Chapter.

Frank earned his Ph.D. from the University of Wisconsin-Madison School of Pharmacy and was a post-doctoral research associate at the University of Illinois-Champaign Urbana.

In her free time, Erin enjoys spending time with friends and family, traveling, and exploring new places.  She spends many hours enjoying the variety of activities of her two daughters.

Erin Lanciani

Senior Vice President, People and Organizational Strategy

Erin joined SAGE in 2014 bringing more than 20 years of experience in developing human resources strategies and programs to the company. Before joining the SAGE team, Erin served as Executive Director, Human Resources, Global Commercialization at Bristol-Myers Squibb (BMS), joining the company through its October 2007 acquisition of Adnexus, where she was the Vice President, Human Resources and a member of the executive leadership team responsible for driving strategy and ensuring a successful integration of Adnexus into BMS. In 2009, Erin relocated to Paris where she was the HR Director for European Markets at BMS, serving as the strategic business partner responsible for all aspects of HR across multiple European commercial, R&D and corporate functions.

Prior to BMS, Erin was Vice President of Human Resources at Therion Biologics Corporation, where she was instrumental in defining and creating the company's culture and HR infrastructure. Prior to Therion, she served as the Director of Human Resources for ViaCell and as a Human Resources Business Partner at Genzyme Corporation for the therapeutics and international divisions and was a Founder/Partner of Outsourcing Solutions, Inc., a human resources consulting firm.

Erin earned her B.S. in Business Administration from Northeastern University.

Amy spends most of her spare time with family and friends, including her husband, two daughters and a rescued Golden Doodle named Sandy. Her hidden talents include playing piano, gardening and sewing (a lost art!).

Amy Schacterle, Ph.D.

Vice President of Regulatory Affairs and Quality Assurance

Amy brings to SAGE extensive expertise in regulatory affairs and quality assurance, with more than 20 years of experience in the biotech and life science industries, including more than 15 years in executive management. She most recently served as Vice President, Regulatory Affairs at Sunovion Pharmaceuticals (previously Sepracor), where she worked for 10 years, also serving as Executive Director and Senior Director of Regulatory Affairs. At Sunovion, she led regulatory strategy regarding clinical development of CNS compounds and later managed development and commercial regulatory activities for all drug, biologic and combination device products at the company's Marlborough campus. Prior to Sunovion, Amy spent seven years leading the regulatory affairs function at Stryker Biotech, where she determined successful regulatory strategies for biologic orthopaedic products and was an integral part of the quality team.

Amy received her B.S. in biomedical engineering at Rensselaer Polytechnic Institute and her Ph.D. and M.S. in biomedical engineering at the University of Virginia. She was recently named as one of the Boston Business Journal/Mass High Tech 2014 Women to Watch.

Ryan enjoys all things sports, cinema and travel- including stand-up paddleboarding with his wife, coaching his son’s sports teams, settling down for a good movie and traveling to warmer climates with his family.

Ryan Arnold, D.O. 

Vice President, Medical Affairs 

Ryan joined SAGE in 2015 as Vice President, Medical Affairs. Before joining SAGE, he served as Senior Director, Medical Affairs and Head U.S. MSLs, at Biogen. He was responsible for leading the field medical affairs organization and national directors that provided coverage for Biogen's Neurology and Hematology portfolios and all pipeline products. He was also instrumental in the development and execution of medical plans and lifecycle strategies for existing products and multiple product launches. Ryan has over 15 years of medical affairs strategic and tactical leadership experience, initially starting as a medical science liaison at Amgen before taking on roles of increasing responsibility at Genzyme, Avanir and Biogen.

Ryan holds a B.A. in biology from Oakland University and a D.O. from Michigan State University College of Osteopathic Medicine.

Board of Directors

Kevin is a proven operational leader with more than 25 years of experience building and operating leading biotech companies. Kevin co-founded Third Rock Ventures in 2007 and focuses on the formation, development and business strategy of the firm's portfolio companies as well as actively identifying and evaluating new investments. Prior to Third Rock Ventures, Kevin was Chief Operating Officer and Chief Financial Officer at Millennium Pharmaceuticals, where he led key roles in raising billions of dollars in capital through strategic alliances and public financing and driving growth through company expansion and mergers and acquisitions. Earlier in his career, he served in various executive roles at Millennium BioTherapeutics, Biogen and Digital Equipment Corporation. He is currently a Board Member of Alnylam Pharmaceuticals.

Kevin holds a M.S. in Corporate Finance from Boston College and a B.A. in Mathematics and Business from Colby College.

Jeff joined SAGE as CEO in 2013 and has more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the CNS field. Before joining the SAGE team, Jeff served as President of the Regenerative Medicine Division of Shire plc and previously as Senior Vice President of Research and Development, Pharmaceuticals at Shire. Prior to Shire, he served as the Executive Vice President of ISIS Pharmaceuticals, as the Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and in senior-level positions at Upjohn Laboratories. Jeff founded AVAX Technologies, where he served as CEO and President, and SCEPTOR Industries, where he served as Chairman, President and Chief Technology Officer. Earlier in his career, he served as Independent Director at Cara Therapeutics, Inc. and Director of AVAX Technologies. He has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts, and has received numerous awards.

Jeff received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard and then served as Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School.

Steven has had a distinguished career in neuroscience, particularly in CNS drug discovery and development. Steven is the former President of the Lilly Research Laboratories of Eli Lilly and Company and now leads the Helen & Robert Appel Institute for Alzheimer's Research at Weill Cornell Medical College. Prior to his appointment at Weill Cornell, Steven spent 17-years at Eli Lilly, during which time he held several key leadership roles, including Vice President of Neuroscience (CNS) Research and Group Vice President of Discovery Research (all therapeutic areas). In his most recent role, he was responsible for the company's overall research and development efforts – helping to expand Lilly's R&D efforts in oncology and biotechnology – resulting in a pipeline of approximately 70 new molecular entities. Prior to Lilly, Steven served as Scientific Director of the National Institute of Mental Health. He has also served as Medical Director in the Commissioned Corps of the United States Public Health Service.

Steven has been the recipient of many awards and honors and has served on numerous committees and advisory boards. He has also authored or co-authored more than 500 papers and book chapters. Steven is an elected fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. He is also currently on the board of directors or is a trustee of several organizations, including the Sigma-Aldrich Corporation, Alnylam Pharmaceuticals, Allen Institute for Brain Science, The Mind Research Network and the Foundation for the NIH. Dr. Paul has also served as a member of the National Institute of General Medical Sciences (NIGMS) Advisory Council and was appointed by the Secretary of the Department of Health and Human Services (HHS) as a member of the advisory committee to the Director of the NIH from 2001-2006. Steven is currently a member of the National Advisory Mental Health Council, NIMH, and is board certified by the American Board of Psychiatry and Neurology.

Steven received his B.A. in Biology and Psychology from Tulane University, and his M.S. and M.D. degrees from the Tulane University School of Medicine.

Howard has been a Chairman of Vanda Pharmaceuticals, a CNS development company, and Lead Independent Director of ViroPharma, Inc., an orphan disease company. Additionally, he currently sits on the Board of Directors of Immunogen, Inc. and Juno Therapeutics, and is also an Advisor to the life sciences practice of Warburg Pincus. He is the former Chief Executive Officer and Chairman of Medarex, Inc., where he served for two years prior to the company’s acquisition by Bristol-Myers Squibb Company in 2009. While at Medarex, Howard shepherded the evolution of the company from a technology platform enterprise to a promising developer of oncology and immunology product candidates. Prior to Medarex, he served as President and Chief Executive Officer of Chiron Corporation from 2003 until its acquisition by Novartis in 2006. Howard held an 11-year tenure at GlaxoSmithKline and its predecessor, SmithKline Beecham, most recently serving as President of GlaxoSmithKline International. Earlier in his career, Howard held roles of increasing responsibility at Abbott Laboratories and at Merck & Co.

Howard completed his MBA in finance at Carnegie Mellon University and his B.S. in civil engineering from Massachusetts Institute of Technology.

Jim serves as Senior Vice President and Chief Financial Officer of Alkermes. Prior to joining Alkermes in 1998, Jim was a Vice President in charge of the East Coast Life Sciences Practice at Robertson Stephens & Company. He also worked in healthcare investment banking at Morgan Stanley & Company and spent a year teaching secondary school at the Royal Shrewsbury School in the U.K., as the Harvard College Fellow. Jim served on the Board of Directors of GPC Biotech AG from June 2004 to June 2009 and was a national director of the Association of Bioscience Financial Officers. He also serves as a Trustee and Treasurer of St. Paul's School. Jim received a Bachelor of Arts degree in government from Harvard College and a Master of Business Administration from Harvard Graduate School of Business Administration.

Michael currently serves as president and chief executive officer of Medgenics, Inc. Prior to joining Medgenics, he served as president of specialty pharmaceuticals at Shire plc, a global specialty pharmaceutical company he first joined in 2005 as executive vice-president of global therapeutic business units and portfolio management. Previously, Michael also served as a growth capital provider and president of the life sciences group for Safeguard Scientifics, Inc., where he served as chairman and chief executive officer of Clarient, Inc., and chairman of Laureate Pharma, Inc. In addition, Michael has held senior positions in product development and commercialization at AstraMerck and AstraZeneca.

Michael received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He also serves on the board of directors at Vanda Pharmaceuticals Inc. and Pennsylvania BIO, and serves as chairman for the board of governors of the Boys & Girls Clubs of Philadelphia.

Geno was recently appointed President of Intrexon, a leader in synthetic biology, effective June 1, 2016.  As President, Mr. Germano is responsible for leading Intrexon's management team and commercialization efforts utilizing the Company's technology platform for biologically-based solutions across a broad range of industries including Health, Consumer, Energy, Environment and Food. 

Mr. Germano has over 30 years of experience in the pharmaceutical industry and a consistent track record of improving operating performance and increasing shareholder value across numerous leadership roles in multiple therapeutic categories and global markets at Pfizer, Wyeth and Johnson & Johnson.  Prior to joining Intrexon, he was Group President of Pfizer's Global Innovative Pharma Business, where he led a growing global $14 billion business with market-leading medicines and an extensive portfolio of late-stage development candidates in several therapeutic areas including cardiovascular, metabolic disease, neuroscience, inflammation, immunology, and rare diseases.  Mr. Germano was also Co-Chair of the Portfolio Strategy and Investment Committee focused on maximizing the return on research and development investment across the Pfizer portfolio. Previously, Mr. Germano served as President and General Manager of Pfizer's Specialty Care and Oncology business units where he led commercial, medical, and post proof-of-concept pipeline strategy and development across global markets, as well as held responsibility for driving P&L growth and pipeline value through disciplined portfolio management.  In addition, while in this role he directed the integration of Wyeth and Pfizer Specialty Care and Vaccines Businesses and developed top talent within the organization focusing on the leadership team.

Prior to joining Pfizer, Mr. Germano held numerous executive and leadership roles at Wyeth Pharmaceuticals including President of Wyeth U.S., where he was responsible for delivery of operational results across four business units, as well as President of its Global Pharmaceutical and Women's Healthcare Business.  He is a member of the Group of Fifty (G50) and serves on the Board of the Biotechnology Innovation Organization, as well as on the Advisory Board of the Healthcare Businesswomen's Association and as a Trustee of the Albany College of Pharmacy where he received his Bachelor of Science degree in Pharmacy.